PROCEEDS AGREEMENTProceeds Agreement • April 24th, 2020 • Baker Bros. Advisors Lp • Biological products, (no disgnostic substances) • New York
WHEREAS, the Agent, in his capacity as a director of Seattle Genetics, Inc. (the “Company”), received non-transferable options (the “Options”) to purchase 17,500 shares of the Company common stock (the “Stock”) according to the below Schedule A;
Loan Agreement Between Baker Brothers Life Sciences, L.P., 667, L.P., and Baker Bros. Advisors LPLoan Agreement • April 24th, 2020 • Baker Bros. Advisors Lp • Biological products, (no disgnostic substances) • New York
For value received, Baker Bros. Advisors LP (the “Management Company”) promises to pay Baker Brothers Life Sciences, L.P., and 667, L.P., (collectively “The Funds”), the amounts set forth in Schedule A below, payable on the Due Date (as defined below) with interest payable through the Due Date at a rate of 1.44% annually.
